Compare IDEXX Laboratories, Inc. (IDXX) vs Omnicom Group Inc. (OMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Omnicom Group Inc. — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while Omnicom Group Inc. trades at $76.46 (market cap $20.97B). The key difference: IDEXX Laboratories, Inc. is the larger of the two by market cap, and Omnicom Group Inc. pays a 4.19% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and Omnicom Group Inc. for 63 Days on average.
| IDXX | OMC | |
|---|---|---|
Market Cap | $40.43B | $20.97B |
Volume | 692,164 | 2,092,899 |
Sector | Health | Media |
52-Week High | $766.68 | $88.94 |
52-Week Low | $504.70 | $67.27 |
Typical Hold Time | 46 Days | 63 Days |
Enterprise Value | $41.32B | $29.05B |
Dividend Yield | — | 4.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $518.00, up 2.24% with strong earnings beats in recent quarters. The stock shows bearish technical signals but maintains robust fundamentals with 25.03% net margins and 74.21% ROE. Recent acquisitions like CoVetAI and product expansions highlight growth initiatives. Analyst consensus remains bullish with a $665 price target, though technical indicators suggest near-term caution.
Outlook remains positive driven by diagnostic innovation and recurring revenue growth, but faces headwinds from FX volatility and weaker U.S. vet visits. The 36.06 P/E ratio reflects premium valuation, requiring sustained execution. Risks include competitive pressures and insider selling, while institutional ownership trends show mixed signals.
Omnicom Group (OMC) trades at $76.48, up 2.15% with mixed technical signals showing bullish overall but bearish moving averages. The company reported strong revenue growth to $17.27B in 2025 but posted a net loss of -$54.50M due to higher taxes. Recent news highlights leadership in digital marketing and $3.3B in new H1 2026 billings, while analyst consensus remains cautious with 58.83% hold ratings.
OMC presents a value opportunity with attractive P/S of 0.86 and consensus price target of $100.50 offering 31% upside, though high P/E of 206.62 and recent earnings misses pose concerns. Key risks include advertising market volatility and debt levels, while AI capabilities and post-Interpublic synergies provide growth catalysts for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Omnicom Group Inc.
Omnicom is the world's second- largest ad holding company, based on annual revenue. The firm's services, which include traditional and digital advertising and public relations, are provided worldwide, with over 85% of its revenue coming from more developed regions such as North America and Europe.
Read more on OMC →
